Four Days Left To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before The Ex-Dividend Date
Four Days Left To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before The Ex-Dividend Date
Jacobson Pharma Corporation Limited (HKG:2633) is about to trade ex-dividend in the next 4 days. The ex-dividend date occurs one day before the record date which is the day on which shareholders need to be on the company's books in order to receive a dividend. The ex-dividend date is of consequence because whenever a stock is bought or sold, the trade takes at least two business day to settle. In other words, investors can purchase Jacobson Pharma's shares before the 3rd of September in order to be eligible for the dividend, which will be paid on the 4th of October.
雅各臣科研製藥有限公司(HKG:2633)即將在接下來的4天內開多分紅派息。分紅除淨日發生在紀錄日的前一天,紀錄日是股東需要在公司賬簿上登記以便領取分紅的日子。分紅除淨日很重要,因爲每次股票的買賣交易至少需要兩個工作日來結算。換句話說,投資者可以在9月3日之前買入雅各臣科研製藥的股票,以符合獲得分紅的資格,分紅將於10月4日支付。
The company's next dividend payment will be HK$0.03 per share, on the back of last year when the company paid a total of HK$0.055 to shareholders. Last year's total dividend payments show that Jacobson Pharma has a trailing yield of 9.2% on the current share price of HK$0.60. Dividends are a major contributor to investment returns for long term holders, but only if the dividend continues to be paid. We need to see whether the dividend is covered by earnings and if it's growing.
公司的下一個分紅支付將是每股0.03港元,在去年公司向股東支付了總額爲0.055港元的情況下。去年的總分紅顯示雅各臣科研製藥目前每股0.60港元的股價有着9.2%的滾動收益率。分紅對於長期股東投資回報是一個重要貢獻者,但前提是分紅持續支付。我們需要看分紅是否有盈利覆蓋以及是否在增長。
Dividends are usually paid out of company profits, so if a company pays out more than it earned then its dividend is usually at greater risk of being cut. Jacobson Pharma paid out more than half (57%) of its earnings last year, which is a regular payout ratio for most companies. Yet cash flow is typically more important than profit for assessing dividend sustainability, so we should always check if the company generated enough cash to afford its dividend. Fortunately, it paid out only 26% of its free cash flow in the past year.
分紅通常由公司利潤支付,所以如果一家公司支付的分紅超過了其盈利,那麼它的股息通常面臨更大的被削減風險。雅各臣科研製藥去年支付了超過一半(57%)的盈利,這是大多數公司的常規支付比率。然而,現金流通常比利潤更重要,用於評估分紅的持續性,所以我們應該始終檢查公司是否產生足夠的現金來支付其分紅。幸運的是,它在過去一年中僅支付了其自由現金流的26%。
It's positive to see that Jacobson Pharma's dividend is covered by both profits and cash flow, since this is generally a sign that the dividend is sustainable, and a lower payout ratio usually suggests a greater margin of safety before the dividend gets cut.
看到雅各臣科研製藥的分紅既獲利蓋得住也被現金流覆蓋,這通常是分紅持續支付的跡象,而較低的支付比率通常意味着在分紅被削減之前有更大的安全邊際。
Click here to see how much of its profit Jacobson Pharma paid out over the last 12 months.
點擊這裏查看雅各臣科研製藥過去12個月中支付了多少利潤。
![1724972184594](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240830/43089350-0-bdc433f2fd59a62b210ce7638bff8291.webp/bigjpg)
Have Earnings And Dividends Been Growing?
收益和股息一直在增長嗎?
When earnings decline, dividend companies become much harder to analyse and own safely. Investors love dividends, so if earnings fall and the dividend is reduced, expect a stock to be sold off heavily at the same time. Readers will understand then, why we're concerned to see Jacobson Pharma's earnings per share have dropped 5.8% a year over the past five years. Such a sharp decline casts doubt on the future sustainability of the dividend.
當盈利下滑,分紅公司會變得更難分析和安全擁有。投資者喜歡分紅,所以如果盈利下降並且分紅減少,預計股票會大幅拋售。讀者將理解我們爲什麼擔心雅各臣科研製藥過去五年每股收益下降了5.8%。如此大幅跌幅對分紅的未來可持續性產生了懷疑。
Another key way to measure a company's dividend prospects is by measuring its historical rate of dividend growth. In the past eight years, Jacobson Pharma has increased its dividend at approximately 17% a year on average. Growing the dividend payout ratio while earnings are declining can deliver nice returns for a while, but it's always worth checking for when the company can't increase the payout ratio any more - because then the music stops.
衡量一家公司的分紅前景的另一種關鍵方法是衡量其歷史分紅增長率。在過去八年中,雅各臣科研製藥的分紅每年平均增長約17%。在盈利下降的情況下增加分紅支付比率可能會帶來一段時間不錯的回報,但是值得檢查的是當公司無法再增加分紅支付比率時,音樂停止了。
The Bottom Line
還有一件事需要注意的是,我們已經確定了上海醫藥的2個警告信號,了解這些信號應該成爲你的投資過程的一部分。
Is Jacobson Pharma worth buying for its dividend? We're not enthused by the declining earnings per share, although at least the company's payout ratio is within a reasonable range, meaning it may not be at imminent risk of a dividend cut. While it does have some good things going for it, we're a bit ambivalent and it would take more to convince us of Jacobson Pharma's dividend merits.
雅各臣科研製藥是否值得購買分紅?我們對每股盈利的下降並不感到興奮,儘管公司的分紅支付比率處於合理範圍內,這意味着它可能不會立即面臨分紅削減的風險。雖然它有一些優點,但我們對雅各臣科研製藥的分紅價值還持有矛盾態度,需要更多的說服力才能讓我們相信它。
If you're not too concerned about Jacobson Pharma's ability to pay dividends, you should still be mindful of some of the other risks that this business faces. Our analysis shows 3 warning signs for Jacobson Pharma that we strongly recommend you have a look at before investing in the company.
如果您不太擔心雅各臣科研製藥支付分紅的能力,仍應注意該業務面臨的其他風險。我們的分析顯示了雅各臣科研製藥存在3個警告信號,強烈建議您在投資該公司之前查看這些警告信號。
Generally, we wouldn't recommend just buying the first dividend stock you see. Here's a curated list of interesting stocks that are strong dividend payers.
一般來說,我們不建議僅僅購買第一個股息股票。下面是一個經過策劃的有趣的、股息表現良好的股票清單。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。